23 Jan 2024 13:57
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Result of AGM
23 January 2024 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that at its Annual General Meeting, held today at 11.30 a.m., (GMT) all resolutions were duly passed.
- Ends -
Contacts
C4X Discovery Holdings |
|
Mo Noonan, Communications | +44 (0)787 6444977 |
|
|
Panmure Gordon (UK) Limited (NOMAD and Broker) |
|
Freddy Crossley, Emma Earl (Corporate Finance) | +44 (0)20 7886 2500 |
Rupert Dearden (Corporate Broking) | |
|
|
C4X Discovery Media - ICR Consilium |
|
Mary-Jane Elliott, Chris Gardner, Matthew Neal | +44 (0)203 709 5700 |
C4X Discovery Holdings |
Notes to Editors:
About C4X Discovery
C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world?leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. We are advancing our internal portfolio which ranges
from early-stage target opportunities to late-stage Drug Discovery programmes and we have two commercially partnered programmes with Sanofi and AstraZeneca, and one clinical stage candidate which has been acquired by Indivior.
For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery.
C4XD.L (C4XD)